Modulation of the immune response to the severe acute respiratory syndrome spike glycoprotein by gene-based and inactivated virus immunization.
Identifieur interne : 002474 ( PubMed/Corpus ); précédent : 002473; suivant : 002475Modulation of the immune response to the severe acute respiratory syndrome spike glycoprotein by gene-based and inactivated virus immunization.
Auteurs : Wing-Pui Kong ; Ling Xu ; Konrad Stadler ; Jeffrey B. Ulmer ; Sergio Abrignani ; Rino Rappuoli ; Gary J. NabelSource :
- Journal of virology [ 0022-538X ] ; 2005.
English descriptors
- KwdEn :
- Animals, Antibody Formation, CD8-Positive T-Lymphocytes (immunology), Humans, Immunity, Cellular, Membrane Glycoproteins (immunology), Mice, Models, Animal, SARS Virus (immunology), Severe Acute Respiratory Syndrome (immunology), Spike Glycoprotein, Coronavirus, Vaccines, DNA, Vaccines, Inactivated, Viral Envelope Proteins (immunology), Viral Vaccines.
- MESH :
- chemical , immunology : Membrane Glycoproteins, Viral Envelope Proteins.
- immunology : CD8-Positive T-Lymphocytes, SARS Virus, Severe Acute Respiratory Syndrome.
- Animals, Antibody Formation, Humans, Immunity, Cellular, Mice, Models, Animal, Spike Glycoprotein, Coronavirus, Vaccines, DNA, Vaccines, Inactivated, Viral Vaccines.
Abstract
Although the initial isolates of the severe acute respiratory syndrome (SARS) coronavirus (CoV) are sensitive to neutralization by antibodies through their spike (S) glycoprotein, variants of S have since been identified that are resistant to such inhibition. Optimal vaccine strategies would therefore make use of additional determinants of immune recognition, either through cellular or expanded, cross-reactive humoral immunity. Here, the cellular and humoral immune responses elicited by different combinations of gene-based and inactivated viral particles with various adjuvants have been assessed. The T-cell response was altered by different prime-boost immunizations, with the optimal CD8 immunity induced by DNA priming and replication-defective adenoviral vector boosting. The humoral immune response was enhanced most effectively through the use of inactivated virus with adjuvants, either MF59 or alum, and was associated with stimulation of the CD4 but not the CD8 response. The use of inactivated SARS virus with MF59 enhanced the CD4 and antibody response even after gene-based vaccination. Because both cellular and humoral immune responses are generated by gene-based vaccination and inactivated viral boosting, this strategy may prove useful in the generation of SARS-CoV vaccines.
DOI: 10.1128/JVI.79.22.13915-13923.2005
PubMed: 16254327
Links to Exploration step
pubmed:16254327Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Modulation of the immune response to the severe acute respiratory syndrome spike glycoprotein by gene-based and inactivated virus immunization.</title><author><name sortKey="Kong, Wing Pui" sort="Kong, Wing Pui" uniqKey="Kong W" first="Wing-Pui" last="Kong">Wing-Pui Kong</name><affiliation><nlm:affiliation>Vaccine Research Center, National Institute for Allergy and Infectious Diseases, National Institutes of Health, Bldg. 40, Room 4502, MSC-3005, 40 Convent Drive, Bethesda, Maryland 20892-3005, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Xu, Ling" sort="Xu, Ling" uniqKey="Xu L" first="Ling" last="Xu">Ling Xu</name></author><author><name sortKey="Stadler, Konrad" sort="Stadler, Konrad" uniqKey="Stadler K" first="Konrad" last="Stadler">Konrad Stadler</name></author><author><name sortKey="Ulmer, Jeffrey B" sort="Ulmer, Jeffrey B" uniqKey="Ulmer J" first="Jeffrey B" last="Ulmer">Jeffrey B. Ulmer</name></author><author><name sortKey="Abrignani, Sergio" sort="Abrignani, Sergio" uniqKey="Abrignani S" first="Sergio" last="Abrignani">Sergio Abrignani</name></author><author><name sortKey="Rappuoli, Rino" sort="Rappuoli, Rino" uniqKey="Rappuoli R" first="Rino" last="Rappuoli">Rino Rappuoli</name></author><author><name sortKey="Nabel, Gary J" sort="Nabel, Gary J" uniqKey="Nabel G" first="Gary J" last="Nabel">Gary J. Nabel</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2005">2005</date><idno type="RBID">pubmed:16254327</idno><idno type="pmid">16254327</idno><idno type="doi">10.1128/JVI.79.22.13915-13923.2005</idno><idno type="wicri:Area/PubMed/Corpus">002474</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002474</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Modulation of the immune response to the severe acute respiratory syndrome spike glycoprotein by gene-based and inactivated virus immunization.</title><author><name sortKey="Kong, Wing Pui" sort="Kong, Wing Pui" uniqKey="Kong W" first="Wing-Pui" last="Kong">Wing-Pui Kong</name><affiliation><nlm:affiliation>Vaccine Research Center, National Institute for Allergy and Infectious Diseases, National Institutes of Health, Bldg. 40, Room 4502, MSC-3005, 40 Convent Drive, Bethesda, Maryland 20892-3005, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Xu, Ling" sort="Xu, Ling" uniqKey="Xu L" first="Ling" last="Xu">Ling Xu</name></author><author><name sortKey="Stadler, Konrad" sort="Stadler, Konrad" uniqKey="Stadler K" first="Konrad" last="Stadler">Konrad Stadler</name></author><author><name sortKey="Ulmer, Jeffrey B" sort="Ulmer, Jeffrey B" uniqKey="Ulmer J" first="Jeffrey B" last="Ulmer">Jeffrey B. Ulmer</name></author><author><name sortKey="Abrignani, Sergio" sort="Abrignani, Sergio" uniqKey="Abrignani S" first="Sergio" last="Abrignani">Sergio Abrignani</name></author><author><name sortKey="Rappuoli, Rino" sort="Rappuoli, Rino" uniqKey="Rappuoli R" first="Rino" last="Rappuoli">Rino Rappuoli</name></author><author><name sortKey="Nabel, Gary J" sort="Nabel, Gary J" uniqKey="Nabel G" first="Gary J" last="Nabel">Gary J. Nabel</name></author></analytic><series><title level="j">Journal of virology</title><idno type="ISSN">0022-538X</idno><imprint><date when="2005" type="published">2005</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antibody Formation</term><term>CD8-Positive T-Lymphocytes (immunology)</term><term>Humans</term><term>Immunity, Cellular</term><term>Membrane Glycoproteins (immunology)</term><term>Mice</term><term>Models, Animal</term><term>SARS Virus (immunology)</term><term>Severe Acute Respiratory Syndrome (immunology)</term><term>Spike Glycoprotein, Coronavirus</term><term>Vaccines, DNA</term><term>Vaccines, Inactivated</term><term>Viral Envelope Proteins (immunology)</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Membrane Glycoproteins</term><term>Viral Envelope Proteins</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>CD8-Positive T-Lymphocytes</term><term>SARS Virus</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Antibody Formation</term><term>Humans</term><term>Immunity, Cellular</term><term>Mice</term><term>Models, Animal</term><term>Spike Glycoprotein, Coronavirus</term><term>Vaccines, DNA</term><term>Vaccines, Inactivated</term><term>Viral Vaccines</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Although the initial isolates of the severe acute respiratory syndrome (SARS) coronavirus (CoV) are sensitive to neutralization by antibodies through their spike (S) glycoprotein, variants of S have since been identified that are resistant to such inhibition. Optimal vaccine strategies would therefore make use of additional determinants of immune recognition, either through cellular or expanded, cross-reactive humoral immunity. Here, the cellular and humoral immune responses elicited by different combinations of gene-based and inactivated viral particles with various adjuvants have been assessed. The T-cell response was altered by different prime-boost immunizations, with the optimal CD8 immunity induced by DNA priming and replication-defective adenoviral vector boosting. The humoral immune response was enhanced most effectively through the use of inactivated virus with adjuvants, either MF59 or alum, and was associated with stimulation of the CD4 but not the CD8 response. The use of inactivated SARS virus with MF59 enhanced the CD4 and antibody response even after gene-based vaccination. Because both cellular and humoral immune responses are generated by gene-based vaccination and inactivated viral boosting, this strategy may prove useful in the generation of SARS-CoV vaccines.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16254327</PMID><DateCompleted><Year>2006</Year><Month>01</Month><Day>27</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-538X</ISSN><JournalIssue CitedMedium="Print"><Volume>79</Volume><Issue>22</Issue><PubDate><Year>2005</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Journal of virology</Title><ISOAbbreviation>J. Virol.</ISOAbbreviation></Journal><ArticleTitle>Modulation of the immune response to the severe acute respiratory syndrome spike glycoprotein by gene-based and inactivated virus immunization.</ArticleTitle><Pagination><MedlinePgn>13915-23</MedlinePgn></Pagination><Abstract><AbstractText>Although the initial isolates of the severe acute respiratory syndrome (SARS) coronavirus (CoV) are sensitive to neutralization by antibodies through their spike (S) glycoprotein, variants of S have since been identified that are resistant to such inhibition. Optimal vaccine strategies would therefore make use of additional determinants of immune recognition, either through cellular or expanded, cross-reactive humoral immunity. Here, the cellular and humoral immune responses elicited by different combinations of gene-based and inactivated viral particles with various adjuvants have been assessed. The T-cell response was altered by different prime-boost immunizations, with the optimal CD8 immunity induced by DNA priming and replication-defective adenoviral vector boosting. The humoral immune response was enhanced most effectively through the use of inactivated virus with adjuvants, either MF59 or alum, and was associated with stimulation of the CD4 but not the CD8 response. The use of inactivated SARS virus with MF59 enhanced the CD4 and antibody response even after gene-based vaccination. Because both cellular and humoral immune responses are generated by gene-based vaccination and inactivated viral boosting, this strategy may prove useful in the generation of SARS-CoV vaccines.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kong</LastName><ForeName>Wing-pui</ForeName><Initials>WP</Initials><AffiliationInfo><Affiliation>Vaccine Research Center, National Institute for Allergy and Infectious Diseases, National Institutes of Health, Bldg. 40, Room 4502, MSC-3005, 40 Convent Drive, Bethesda, Maryland 20892-3005, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Ling</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Stadler</LastName><ForeName>Konrad</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Ulmer</LastName><ForeName>Jeffrey B</ForeName><Initials>JB</Initials></Author><Author ValidYN="Y"><LastName>Abrignani</LastName><ForeName>Sergio</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Rappuoli</LastName><ForeName>Rino</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Nabel</LastName><ForeName>Gary J</ForeName><Initials>GJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Z01 AI005056-03</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Virol</MedlineTA><NlmUniqueID>0113724</NlmUniqueID><ISSNLinking>0022-538X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019444">Vaccines, DNA</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014759">Viral Envelope Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C578557">spike glycoprotein, SARS-CoV</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000917" MajorTopicYN="N">Antibody Formation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018414" MajorTopicYN="N">CD8-Positive T-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007111" MajorTopicYN="N">Immunity, Cellular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D023421" MajorTopicYN="N">Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019444" MajorTopicYN="N">Vaccines, DNA</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015164" MajorTopicYN="Y">Vaccines, Inactivated</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014759" MajorTopicYN="N">Viral Envelope Proteins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="Y">Viral Vaccines</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>10</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>1</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>10</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16254327</ArticleId><ArticleId IdType="pii">79/22/13915</ArticleId><ArticleId IdType="doi">10.1128/JVI.79.22.13915-13923.2005</ArticleId><ArticleId IdType="pmc">PMC1280202</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Infect Dis. 1993 Mar;167(3):731-5</Citation><ArticleIdList><ArticleId IdType="pubmed">8382722</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2002 Jan 17;415(6869):331-5</Citation><ArticleIdList><ArticleId IdType="pubmed">11797011</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 2005 Mar 1;174(5):2476-80</Citation><ArticleIdList><ArticleId IdType="pubmed">15728450</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2000 Nov 30;408(6812):605-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11117750</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2005 Feb 15;102(7):2430-5</Citation><ArticleIdList><ArticleId IdType="pubmed">15695582</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2005 May 16;23(26):3434-45</Citation><ArticleIdList><ArticleId IdType="pubmed">15837367</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 2005 Mar 30;334(1):134-43</Citation><ArticleIdList><ArticleId IdType="pubmed">15749129</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2005 Jul;79(14):8828-34</Citation><ArticleIdList><ArticleId IdType="pubmed">15994776</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunol Lett. 2004 Sep;95(2):139-43</Citation><ArticleIdList><ArticleId IdType="pubmed">15388253</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2004 Apr 16;22(13-14):1799-809</Citation><ArticleIdList><ArticleId IdType="pubmed">15068864</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2004 Dec 21;23(6):827-39</Citation><ArticleIdList><ArticleId IdType="pubmed">15542208</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2003 May 16;21(17-18):1826-32</Citation><ArticleIdList><ArticleId IdType="pubmed">12706666</ArticleId></ArticleIdList></Reference><Reference><Citation>EMBO J. 2005 Apr 20;24(8):1634-43</Citation><ArticleIdList><ArticleId IdType="pubmed">15791205</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1997 Aug 19;94(17):9378-83</Citation><ArticleIdList><ArticleId IdType="pubmed">9256490</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2004 Jun;78(11):5642-50</Citation><ArticleIdList><ArticleId IdType="pubmed">15140961</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1996 Jul 19;273(5273):352-4</Citation><ArticleIdList><ArticleId IdType="pubmed">8662521</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2004 Mar 12;303(5664):1666-9</Citation><ArticleIdList><ArticleId IdType="pubmed">14752165</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2003 Dec;77(23):12764-72</Citation><ArticleIdList><ArticleId IdType="pubmed">14610198</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2003 Jun;77(11):6305-13</Citation><ArticleIdList><ArticleId IdType="pubmed">12743287</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9804-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15210961</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Biophys Res Commun. 2004 Dec 10;325(2):445-52</Citation><ArticleIdList><ArticleId IdType="pubmed">15530413</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Virol. 2004;48(4):201-14</Citation><ArticleIdList><ArticleId IdType="pubmed">15745043</ArticleId></ArticleIdList></Reference><Reference><Citation>Scand J Immunol. 1999 May;49(5):506-14</Citation><ArticleIdList><ArticleId IdType="pubmed">10320644</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Gene Ther. 2004 Jun;11(6):457-64</Citation><ArticleIdList><ArticleId IdType="pubmed">15118761</ArticleId></ArticleIdList></Reference><Reference><Citation>Infect Immun. 2004 Jan;72(1):253-9</Citation><ArticleIdList><ArticleId IdType="pubmed">14688103</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Rev Vaccines. 2003 Apr;2(2):197-203</Citation><ArticleIdList><ArticleId IdType="pubmed">12899571</ArticleId></ArticleIdList></Reference><Reference><Citation>Infect Immun. 2001 Aug;69(8):4816-22</Citation><ArticleIdList><ArticleId IdType="pubmed">11447155</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2004 Jun 26;363(9427):2139-41</Citation><ArticleIdList><ArticleId IdType="pubmed">15220038</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2004 Apr 16;22(13-14):1782-90</Citation><ArticleIdList><ArticleId IdType="pubmed">15068862</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 1999 Jun 1;162(11):6716-23</Citation><ArticleIdList><ArticleId IdType="pubmed">10352290</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 1999 Nov;180(5):1656-64</Citation><ArticleIdList><ArticleId IdType="pubmed">10515829</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2004 Apr 1;428(6982):561-4</Citation><ArticleIdList><ArticleId IdType="pubmed">15024391</ArticleId></ArticleIdList></Reference><Reference><Citation>Genet Vaccines Ther. 2004 Dec 03;2(1):17</Citation><ArticleIdList><ArticleId IdType="pubmed">15579202</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 1993 May 15;150(10):4672-86</Citation><ArticleIdList><ArticleId IdType="pubmed">8097759</ArticleId></ArticleIdList></Reference><Reference><Citation>Viral Immunol. 2004;17(2):182-96</Citation><ArticleIdList><ArticleId IdType="pubmed">15279698</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1994 Aug 5;265(5173):781-4</Citation><ArticleIdList><ArticleId IdType="pubmed">8047883</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2005 Jan;79(1):393-400</Citation><ArticleIdList><ArticleId IdType="pubmed">15596832</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Investig Drugs. 2002 Mar;3(3):374-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12054082</ArticleId></ArticleIdList></Reference><Reference><Citation>Emerg Infect Dis. 2004 Dec;10(12):2244-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15663874</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2003 Apr 19;361(9366):1319-25</Citation><ArticleIdList><ArticleId IdType="pubmed">12711465</ArticleId></ArticleIdList></Reference><Reference><Citation>Infect Immun. 2001 Jan;69(1):386-91</Citation><ArticleIdList><ArticleId IdType="pubmed">11119528</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2005 Jan 4;23(7):924-31</Citation><ArticleIdList><ArticleId IdType="pubmed">15603894</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):797-801</Citation><ArticleIdList><ArticleId IdType="pubmed">15642942</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Immunol. 1993 Aug;23(8):1757-61</Citation><ArticleIdList><ArticleId IdType="pubmed">8393797</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6641-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15096611</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Virol. 2002 Nov;147(11):2125-41</Citation><ArticleIdList><ArticleId IdType="pubmed">12417948</ArticleId></ArticleIdList></Reference><Reference><Citation>Emerg Infect Dis. 2004 Oct;10(10):1774-81</Citation><ArticleIdList><ArticleId IdType="pubmed">15504263</ArticleId></ArticleIdList></Reference><Reference><Citation>AIDS Res Hum Retroviruses. 2004 Feb;20(2):235-44</Citation><ArticleIdList><ArticleId IdType="pubmed">15018712</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2004 Feb;78(3):1333-43</Citation><ArticleIdList><ArticleId IdType="pubmed">14722288</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Feb 24;101(8):2536-41</Citation><ArticleIdList><ArticleId IdType="pubmed">14983044</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2004 Nov 15;23(1):58-68</Citation><ArticleIdList><ArticleId IdType="pubmed">15519708</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 1998 Jan;4(1):37-42</Citation><ArticleIdList><ArticleId IdType="pubmed">9427604</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2003 Nov 27;426(6965):450-4</Citation><ArticleIdList><ArticleId IdType="pubmed">14647384</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 1991 Mar;181(1):327-35</Citation><ArticleIdList><ArticleId IdType="pubmed">1847259</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2001 Feb 8;19(13-14):1820-6</Citation><ArticleIdList><ArticleId IdType="pubmed">11166907</ArticleId></ArticleIdList></Reference><Reference><Citation>Infect Immun. 1995 Nov;63(11):4261-7</Citation><ArticleIdList><ArticleId IdType="pubmed">7591056</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1998 Feb 13;279(5353):1034-7</Citation><ArticleIdList><ArticleId IdType="pubmed">9461435</ArticleId></ArticleIdList></Reference><Reference><Citation>J Feline Med Surg. 2004 Apr;6(2):111-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15123156</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2005 Jan 4;23(7):847-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15603883</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2003 Oct 10;302(5643):276-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12958366</ArticleId></ArticleIdList></Reference><Reference><Citation>World J Gastroenterol. 2004 Sep 1;10(17):2488-92</Citation><ArticleIdList><ArticleId IdType="pubmed">15300890</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2003 Dec 6;362(9399):1895-6</Citation><ArticleIdList><ArticleId IdType="pubmed">14667748</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2003 Dec;77(23):12907-13</Citation><ArticleIdList><ArticleId IdType="pubmed">14610213</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2005 May 20;23(27):3535-44</Citation><ArticleIdList><ArticleId IdType="pubmed">15855012</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Feb 24;101(8):2542-7</Citation><ArticleIdList><ArticleId IdType="pubmed">14983045</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2004 Jul;78(14):7490-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15220422</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2003 May 30;300(5624):1394-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12730500</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 1999 May;73(5):4120-6</Citation><ArticleIdList><ArticleId IdType="pubmed">10196308</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuberculosis (Edinb). 2003;83(6):339-49</Citation><ArticleIdList><ArticleId IdType="pubmed">14623164</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1986-94</Citation><ArticleIdList><ArticleId IdType="pubmed">12682352</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 1999 Oct;5(10):1157-63</Citation><ArticleIdList><ArticleId IdType="pubmed">10502819</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1953-66</Citation><ArticleIdList><ArticleId IdType="pubmed">12690092</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Rev Vaccines. 2004 Aug;3(4):386</Citation><ArticleIdList><ArticleId IdType="pubmed">15270641</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2004 Feb 13;303(5660):944-6</Citation><ArticleIdList><ArticleId IdType="pubmed">14963300</ArticleId></ArticleIdList></Reference><Reference><Citation>DNA Cell Biol. 2004 Jun;23(6):391-4</Citation><ArticleIdList><ArticleId IdType="pubmed">15231072</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 2003 Dec 15;171(12):6774-9</Citation><ArticleIdList><ArticleId IdType="pubmed">14662882</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2005 Jul;79(13):8024-31</Citation><ArticleIdList><ArticleId IdType="pubmed">15956548</ArticleId></ArticleIdList></Reference><Reference><Citation>Virus Genes. 2005 Jan;30(1):93-102</Citation><ArticleIdList><ArticleId IdType="pubmed">15744567</ArticleId></ArticleIdList></Reference><Reference><Citation>AIDS Rev. 2003 Jul-Sep;5(3):131-9</Citation><ArticleIdList><ArticleId IdType="pubmed">14598562</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002474 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 002474 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:16254327
|texte= Modulation of the immune response to the severe acute respiratory syndrome spike glycoprotein by gene-based and inactivated virus immunization.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:16254327" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |